Industry Trend

Site Sections


Menu













© 2023. All Rights reserved.

Overview for ABBVIE

All Data per May 26, 2023

Industry:

Drug Manufacturers—General

Last Close:

137.56 USD

Expected Dividend:

4.30 %

Payoffs per Year:

4
Business Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.


Competitors View

Ordering

PFIZER

USA
0.89 3.74%
4.36%
6.07% 4.49% 1.0 0.61
-43.29%
46.05 16.02% 48.64 1.0

ABBVIE

USA
1.02 3.5%
4.3%
10.17% 5.07% 1.0 3.15
-14.88%
42.79 13.02% 12.45 2.0

ASTRAZENECA

GBR
1.06 3.6%
2.11%
5.97% 4.3% 0.5 16.21
-3.86%
67.14 17.71% 38.41 3.0

SANOFI

FRA
1.11 3.8%
3.58%
1.59% 3.73% 1.0 0.88
-12.18%
49.68 12.1% 59.3 4.0

CHUGAI PHARMACEUTICAL

JPN
0.98 1.38%
2.08%
16.13% 2.65% 1.0 3.06
-38.8%
42.96 15.38% 77.21 5.0

MERCK & CO.

USA
1.09 3.4%
2.67%
5.29% 3.94% 1.0 3.67
-11.68%
47.47 8.91% 42.19 6.0

BRISTOL-MYERS SQUIBB

USA
0.95 2.6%
4.47%
2.48% 2.66% 1.0 0.53
-24.44%
34.16 17.14% 32.14 7.0

ASTELLAS PHARMA

JPN
1.01 2.35%
2.85%
19.78% 5.38% 1.0 1.47
-19.06%
31.03 -2.41% 62.61 8.0

ELI LILLY AND COMPANY

USA
1.1 2.36%
1.06%
14.8% 4.25% 1.0 11.83
-12.71%
45.05 7.83% 21.77 9.0

AMGEN

USA
0.95 2.75%
3.93%
10.11% 3.97% 1.0 1.83
-17.4%
38.25 -3.13% 5.62 10.0

DAIICHI SANKYO

JPN
1.07 2.05%
0.7%
6.06% 2.46% 1.0 10.21
-17.26%
41.99 11.62% 60.81 11.0

KYOWA HAKKO KOGYO

JPN
0.95 1.65%
1.91%
8.0% 2.16% 1.0 3.07
-15.61%
44.19 3.67% 81.16 12.0

OTSUKA HOLDINGS CO., LTD.

JPN
1.01 2.16%
1.93%
0.0% 1.98% 1.0 0.44
-14.62%
29.23 12.66% 72.92 13.0

ROCHE

CHE
0.92 3.1%
3.27%
1.69% 3.06% 1.0 0.55
-23.37%
40.4 0.0% 36.32 14.0

GILEAD SCIENCES

USA
1.04 3.5%
3.89%
3.61% 3.76% 0.5 0.24
-42.43%
36.76 3.95% 33.57 15.0

JOHNSON & JOHNSON

USA
0.96 2.69%
3.05%
5.9% 3.2% 1.0 0.19
-12.62%
46.37 -0.95% 40.99 16.0

BAYER

GER
1.06 2.96%
3.68%
0.81% 2.81% 0.5 -0.3
-58.76%
37.48 -6.72% 31.17 17.0

GLAXOSMITHKLINE

GBR
1.02 6.49%
2.62%
0.0% 5.95% -1.0 0.02
-24.56%
47.0 -2.84% 16.79 18.0

GRIFOLS SA

ESP
0.91 1.1%
0.0%
-53.18% 0.2% -0.5 -0.11
-65.73%
32.66 2.01% 38.04 19.0


Information for ABBVIE

Yield Triangle

Dividend & Close

Dividend Close Div.-Yield
Year
2023 5.92 137.56 4.30
2022 5.64 161.61 3.49
2021 5.20 135.40 3.84
2020 4.72 107.15 4.41
2019 4.28 88.54 4.83
2018 3.59 91.12 3.94
2017 2.56 96.71 2.65
2016 2.28 62.62 3.64
2015 2.02 59.24 3.41
2014 1.66 65.44 2.54
2013 1.60 52.81 3.03

Fundamentals

Chart